abatacept, Fusion protein of CD80;Fusion protein of CD86, CAS No.rp173355, Fusion protein of CD80;Fusion protein of CD86

Features and benefits

Item Number

rp173355

Grouped product items
SKU	Size	Availability	Price	Qty
rp173355-500μg	500μg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,334.90
rp173355-1mg	1mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,334.90

View related series

Product Name

abatacept, Fusion protein of CD80;Fusion protein of CD86, CAS No.rp173355

Grade

Moligand™

Specifications & Purity

Moligand™

Action Type

INHIBITOR

Mechanism of action

Fusion protein of CD80;Fusion protein of CD86

References

1. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7.. J Exp Med, 174 (3): (561-9). [PMID:1714933] [10.1021/op500134e]
2. Ludvigsson J. (2016) Therapies to Preserve β-Cell Function in Type 1 Diabetes.. Drugs, 76 (2): (169-85). [PMID:26645223] [10.1021/op500134e]
3. Davis IC, Randell J, Davis SN. (2015) Immunotherapies currently in development for the treatment of type 1 diabetes.. Expert Opin Investig Drugs, 24 (10): (1331-41). [PMID:26364507] [10.1021/op500134e]
4. Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, England E, Huntington C, Kemp B et al.. (2017) A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.. J Immunol, 198 (1): (528-537). [PMID:27881707] [10.1021/op500134e]

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description